EP0771202A1 - UTILISATION DE (S)-ADENOSYL-L-METHIONINE (SAMe) ET SES SELS PHYSIOLOGIQUEMENT COMPATIBLES POUR LE TRAITEMENT DE DOMMAGES DE REPERFUSION PROVOQUES PAR ISCHEMIE FOCALE TEMPORAIRE - Google Patents

UTILISATION DE (S)-ADENOSYL-L-METHIONINE (SAMe) ET SES SELS PHYSIOLOGIQUEMENT COMPATIBLES POUR LE TRAITEMENT DE DOMMAGES DE REPERFUSION PROVOQUES PAR ISCHEMIE FOCALE TEMPORAIRE

Info

Publication number
EP0771202A1
EP0771202A1 EP95924974A EP95924974A EP0771202A1 EP 0771202 A1 EP0771202 A1 EP 0771202A1 EP 95924974 A EP95924974 A EP 95924974A EP 95924974 A EP95924974 A EP 95924974A EP 0771202 A1 EP0771202 A1 EP 0771202A1
Authority
EP
European Patent Office
Prior art keywords
same
methionine
reperfusion damage
adenosyl
physiologically compatible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95924974A
Other languages
German (de)
English (en)
Inventor
Laszlo Szabo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Knoll GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Knoll GmbH filed Critical Knoll GmbH
Publication of EP0771202A1 publication Critical patent/EP0771202A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Definitions

  • SAMe -Adenosyl-L-methionine
  • SAMe can be used for various indications relating to central damage.
  • the main manifestations of temporary focal ischemia are the following: (1) acute thromboembolic ischemia, where reperfusion by administration of thrombolytically active substances (such as urokinase, streptokinase or t-PA) or by surgery Measures are initiated, (2) vasospasms that dissolve spontaneously or after administration of vasodilatory substances, (3) surgical interventions, in which the temporary occlusion of an artery is initiated for operational reasons, and (4) transient ischemic attacks with unexplained
  • the present invention relates to the use of SAMe and its physiologically tolerable salts for the treatment of reperfusion damage which is triggered by temporary focal ischemia.
  • SAMe is preferably used in the form of a salt with a physiologically acceptable acid.
  • Preferred acids are: hydrochloric acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, citric acid, tartaric acid, methanesulfonic acid, p-toluenesulfonic acid and butanedisulfonic acid.
  • SAMe or its salts are administered for these indications in an amount of 10 to 1000 mg / kg body weight.
  • SAMe can be administered parenterally (intravenously, intraarterially or intramuscularly) in a customary manner, with intravenous infusion being the preferred form of administration.
  • the above amount is usually infused into the patient once over a period of 1 to 24 hours.
  • SAMe can be applied in the usual galeni Customer application forms liquid, z. B. as a solution.
  • the application forms normally contain the active ingredient in an amount of 1 to 50%, preferably 5 to 20%.
  • the effect of SAMe on the size of the cerebral infarction caused by temporary focal cerebral ischemia was determined in the rat using the modified method of Chen et al. (Stroke 17: 738, 1986). For this, the right-sided A. cerebri media and the two Aa. carotis sess under halothane anesthesia exposed and occluded for 90 min. The size of the cerebral infarction was determined 24 hours later after staining with triphenyltetrazolium chloride.
  • test animals were treated with 40 mg / kg + 100 mg / kg / h SAMe intravenously.
  • the bolus was given either at the end of the 90-minute occlusion or 30 minutes later; the continuous infusion was maintained for 6 hours.
  • Table 1 the temporary vascular occlusion resulted in significantly smaller cerebral infarcts when treated with SAMe than when treated with placebo (0.9% NaCl solution).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne l'utilisation de (S)-adénosyl-L-méthionine (SAMe) et de ses sels physiologiquement compatibles, pour le traitement de dommages de reperfusion provoqués par ischémie focale temporaire.
EP95924974A 1994-07-16 1995-07-05 UTILISATION DE (S)-ADENOSYL-L-METHIONINE (SAMe) ET SES SELS PHYSIOLOGIQUEMENT COMPATIBLES POUR LE TRAITEMENT DE DOMMAGES DE REPERFUSION PROVOQUES PAR ISCHEMIE FOCALE TEMPORAIRE Withdrawn EP0771202A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4425280A DE4425280C2 (de) 1994-07-16 1994-07-16 Verwendung von (S)-Adenosyl-L-methionin und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die nach temporärer fokaler Ischämie ausgelöst werden
DE4425280 1994-07-16
PCT/EP1995/002598 WO1996002252A1 (fr) 1994-07-16 1995-07-05 UTILISATION DE (S)-ADENOSYL-L-METHIONINE (SAMe) ET SES SELS PHYSIOLOGIQUEMENT COMPATIBLES POUR LE TRAITEMENT DE DOMMAGES DE REPERFUSION PROVOQUES PAR ISCHEMIE FOCALE TEMPORAIRE

Publications (1)

Publication Number Publication Date
EP0771202A1 true EP0771202A1 (fr) 1997-05-07

Family

ID=6523426

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95924974A Withdrawn EP0771202A1 (fr) 1994-07-16 1995-07-05 UTILISATION DE (S)-ADENOSYL-L-METHIONINE (SAMe) ET SES SELS PHYSIOLOGIQUEMENT COMPATIBLES POUR LE TRAITEMENT DE DOMMAGES DE REPERFUSION PROVOQUES PAR ISCHEMIE FOCALE TEMPORAIRE

Country Status (18)

Country Link
US (1) US5776911A (fr)
EP (1) EP0771202A1 (fr)
JP (1) JPH10502652A (fr)
KR (1) KR970704442A (fr)
AU (1) AU2927195A (fr)
BG (1) BG101145A (fr)
CA (1) CA2195345A1 (fr)
CZ (1) CZ12297A3 (fr)
DE (1) DE4425280C2 (fr)
FI (1) FI970165A7 (fr)
HR (1) HRP950405A2 (fr)
HU (1) HUT76834A (fr)
IL (1) IL114540A0 (fr)
NO (1) NO970185L (fr)
PL (1) PL318318A1 (fr)
SI (1) SI9520087A (fr)
WO (1) WO1996002252A1 (fr)
ZA (1) ZA955865B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19515275A1 (de) * 1995-04-26 1996-10-31 Knoll Ag Neue Verwendung von (S)-Adenosyl-L-methionin(SAMe)
IT1317920B1 (it) * 2000-10-20 2003-07-15 Univ Roma S-adenosilmetionina e suoi derivati per il trattamento e laprevenzione della malattia di alzheimer.
US8841344B2 (en) 2002-10-03 2014-09-23 Hill's Pet Nutrition, Inc. Method of using omega-3 fatty acids
FR2884421B1 (fr) 2005-04-15 2007-08-10 Virbac Sa Nouveaux moyens de regulation des troubles du comportement chez les animaux de compagnie
WO2006111541A2 (fr) * 2005-04-20 2006-10-26 Basf Plant Science Gmbh Cassettes d'expression pour l'expression preferentielle de semences dans des plantes
US8618355B2 (en) 2008-03-17 2013-12-31 National Research Council Of Canada Aromatic prenyltransferase from hop

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1173990B (it) * 1984-05-16 1987-06-24 Bioresearch Spa Sali stabili della solfo-adenosil-l-metionina (same) particolarmente adatti per uso parenterale
JPH0770235B2 (ja) * 1988-06-24 1995-07-31 株式会社東芝 不揮発性メモリ回路装置
JPH02290896A (ja) * 1989-04-28 1990-11-30 Fuji Kagaku Kogyo Kk 新規なｓ―アデノシルメチオニン誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9602252A1 *

Also Published As

Publication number Publication date
NO970185L (no) 1997-03-12
NO970185D0 (no) 1997-01-15
ZA955865B (en) 1997-01-14
CZ12297A3 (cs) 1998-04-15
MX9700439A (es) 1998-05-31
AU2927195A (en) 1996-02-16
DE4425280A1 (de) 1996-01-18
WO1996002252A1 (fr) 1996-02-01
HUT76834A (en) 1997-11-28
CA2195345A1 (fr) 1996-02-01
KR970704442A (ko) 1997-09-06
HRP950405A2 (en) 1997-10-31
SI9520087A (en) 1997-08-31
US5776911A (en) 1998-07-07
HU9700130D0 (en) 1997-02-28
IL114540A0 (en) 1995-11-27
DE4425280C2 (de) 1997-05-07
BG101145A (bg) 1997-08-29
FI970165L (fi) 1997-03-14
PL318318A1 (en) 1997-06-09
JPH10502652A (ja) 1998-03-10
FI970165A7 (fi) 1997-03-14
FI970165A0 (fi) 1997-01-15

Similar Documents

Publication Publication Date Title
DE68911068T2 (de) EGF zur Vorbeugung von Gewebeschädigung nach Ischemie.
EP0876140B1 (fr) Solutions d'agents de contraste ameliorees pour administration intraveineuse
DE69229975T2 (de) Pharmazeutische Zusammensetzungen, die ein Anticytokin enthalten
De Coul et al. Neuromuscular complications in patients given pavulon/sr (pancuronium bromide) during artificial ventilation
DE60029340T2 (de) Pharmazeutische zusammenstellungen enthaltend einen p2t rezeptor antagonist und melagatran
EP0185210B1 (fr) Utilisation de dérivés dipeptidiques pour la préparation de médicaments pour le traitement des malades atteints de sclérose latérale amyotrophique
DE69232516T2 (de) Behandlung von neurologischen Zuständen durch eine Interleukin-i-inhibierende Verbindung
DE69021415T2 (de) Mittel zur Behandlung von seniler Demenz, Gedächtnisstörungen und ähnlichen Zuständen.
DE3317692A1 (de) Verwendung von metkephamid oder eines pharmazeutisch unbedenklichen salzes hiervon als analgetikum bei traechtigen weiblichen tieren und insbesondere bei schwangeren frauen
EP1170012A1 (fr) PROMOTEURS DE REGENERATION/RECONSTRUCTION CEREBROVASCULAIRE ET INHIBITEURS DE DEGENERATION SECONDAIRE DES TISSUS NERVEUX COMPRENANT DU GINSENOSIDE Rb 1?
EP0363671B1 (fr) Utilisation des inhibiteurs de l'ACE contre la formation des néo-intimes après des endommagements vasculaires
DE4425280C2 (de) Verwendung von (S)-Adenosyl-L-methionin und dessen physiologisch verträglichen Salzen zur Behandlung von Reperfusionsschäden, die nach temporärer fokaler Ischämie ausgelöst werden
DE2900203A1 (de) Krebshemmendes und krebsmetastasen verhinderndes arzneimittel
DE69328792T2 (de) Behandlung von migräne
DE69937574T2 (de) Verwendung des pharmazeutischen präparates "histochrome" zur behandlung des akuten herzinfarkts und ischämischer herzerkrankungen
DE60017733T2 (de) Verwendung von riluzol zur behandlung multipler sklerose
DE69131517T2 (de) Verwendung von Prostaglandin-E1 zur Behandlung männlicher erektiler Impotenz
EP0132595B1 (fr) Agent tocolytique
DE2611976A1 (de) Pharmazeutisches praeparat zur besserung und wiederherstellung bei verminderten bewusstseinszustaenden
EP1603583A2 (fr) Utilisation d'encens ou de ses produits d'hydrogenation en prevention et/ou traitement d'une ischemie cerebrale et/ou d'une lesion cerebrale traumatique
EP0845264A1 (fr) Extrait partiel ou total de Camellia sinensis L. non fermenté
Kross et al. No dantrolene protection in a dog model of complete cerebral ischaemia
DE3744542B4 (de) Pharmazeutische Verwendung von L-δ-Hydroxylysin
DE60225576T2 (de) Verfahren zur unterdrückung der bildung von seromen mit faktor xiii
EP0822820A1 (fr) NOUVELLE UTILISATION DE (S)-ADENOSYL-L-METHIONINE (SAMe)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970114

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19980617